GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Shares Outstanding (EOP)

Thiogenesis Therapeutics (TSXV:TTI) Shares Outstanding (EOP) : 45.50 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Thiogenesis Therapeutics's shares outstanding for the quarter that ended in Mar. 2024 was 45.50 Mil.

Thiogenesis Therapeutics's quarterly shares outstanding increased from Dec. 2023 (44.57 Mil) to Mar. 2024 (45.50 Mil). It means Thiogenesis Therapeutics issued new shares from Dec. 2023 to Mar. 2024 .

Thiogenesis Therapeutics's annual shares outstanding increased from Feb. 2022 (27.91 Mil) to Dec. 2023 (44.57 Mil). It means Thiogenesis Therapeutics issued new shares from Feb. 2022 to Dec. 2023 .


Thiogenesis Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Thiogenesis Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Shares Outstanding (EOP) Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23
Shares Outstanding (EOP)
27.91 27.91 12.00 27.91 44.57

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.86 38.86 38.86 44.57 45.50

Competitive Comparison of Thiogenesis Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Thiogenesis Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thiogenesis Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's Shares Outstanding (EOP) falls into.



Thiogenesis Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Thiogenesis Therapeutics  (TSXV:TTI) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Thiogenesis Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Thiogenesis Therapeutics (TSXV:TTI) Business Description

Traded in Other Exchanges
N/A
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's lead compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live and side effects. TTI-0102's initial applications are for mitochondrial disease, Rett syndrome and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder